Idorsia Pharmaceutical Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Idorsia Pharmaceutical Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 19 Apr 2022 | Lorem |
| LoA Update: Idorsia Pharmaceutical’s neuropathic pain/Fabry disease asset lucerastat sees its trial advancement stumble after Phase III Fabry disease bomb | 14 Oct 2021 | Adam Zamecnik |
| Idorsia’s Phase III lucerastat in Fabry disease has experts doubtful of 30% neuropathic pain reduction value; Phase I data lacks clinical gravitas | 12 Feb 2020 | Ayisha Sharma |
| Idorsia's daridorexant uptake potential in insomnia could be a snooze due to entrenched competitor, despite likely Phase III success and FDA approval, experts say | 11 Dec 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer